AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
SATRALIZUMAB
3 registrations across 3 African markets— 1 active
Markets with SATRALIZUMAB
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| Enspryng Solution for Injection** Solution for injection | 🇳🇬Nigeria | Roche Products Limited | active | Aug 2028 |
| ENSPRYNG 120MG/ML | 🇬🇭Ghana | — | expired | Jun 2026 |
| ENSPRYNG | 🇿🇦South Africa | Roche Products (Pty) Ltd | suspended | Jul 2025 |
SATRALIZUMAB in Africa — Regulatory Overview
SATRALIZUMAB is registered across 3 African markets with 3 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Ghana, Nigeria, South Africa. AfricaRegulatory refreshes this data daily from official government sources.
Of the 3 registrations, 1 (33%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.